WANT A PROFILE LIKE THIS?
Create my FREE Plan Or learn about other options
Tanya Camacho-Villegas
PeerJ Editor, Author & Reviewer
1,015 Points

Contributions by role

Reviewer 15
Editor 1,000

Contributions by subject area

Immunology
Infectious Diseases
Molecular Biology
Cardiology
Women's Health
Histology
Biotechnology
Allergy and Clinical Immunology
Oncology
Pathology
Global Health
HIV
Psychiatry and Psychology
Cell Biology
Rheumatology
Bioengineering
Dermatology
Clinical Trials
Drugs and Devices
Gynecology and Obstetrics
Parasitology
Hematology
Translational Medicine

Tanya Amanda Camacho-Villegas

PeerJ Editor, Author & Reviewer

Summary

Tanya Camacho-Villegas is a Researcher for Mexico in the Medical and Pharmaceutical Biotechnology Unit, CIATEJ, A.C., located in Guadalajara, Jalisco, Mexico (2014-present). She is a member of the Mexican National System of Researchers level I. She works in recombinant protein design, cloning, and production (batch and bioreactor scale). She specializes in phage display for isolating single-domain antibodies such as vNAR´s or peptide isolation with diagnostic applications. Recently, she used the vNAR as an immuno-carrier for NPs for theranostics applications for breast cancer and glioblastomas as models.
She has received a BSc in Biology from the Science Faculty, UABC (2004) and a Marine Biotechnology MSc in CICESE (2007) focusing on the selection and validation of vNARs with anti-cytokines properties as candidates for TNFalpha and VEGF165 neutralizing in humans disorders.
She has received a PhD in Molecular Ecology and Biotechnology from the Marine Science Faculty at UABC (2012). She received a distinction in the Ph.D. dissertation
and fellowships from CONAHCYT for MSc, Ph.D., and Postdoc studies. She was the leader of four projects related to biotechnology companies. She was the author of patents related to vNAR as anti-cytokines or immuno-carriers for drug delivery.

Allergy & Clinical Immunology Bioengineering Biomaterials Biotechnology Cell Biology Composites Gels Immunology Infectious Diseases Molecular Biology Nano & Microstructured Materials Oncology Raman Spectroscopy Sensors Synthetic Biology

Editorial Board Member

PeerJ - the Journal of Life & Environmental Sciences

Work details

Researcher

CIATEJ
September 2014
Medical Biotechnology and Pharmaceutical Unit
We are at a crucial moment for science focused on the application, therefore, it is in our interest to develop innovative projects focused on the production of recombinant antibodies such as vNAR, scFv or peptides with theranostic applications against breast cancer or glioblastoma as models. Also, we are interested in using vNAR's for therapy or diagnosis with an impact on animal health. In several collaborations, we have used peptides or recombinant antibodies to functionalize nanoparticles or liposomes, generating nanosystems for the delivery of drugs or theranostic mainly for breast cancer. In addition, we collaborate in obtaining peptides to develop a POC for diseases transmitted by vectors. Likewise, we carry out the production of recombinant proteins in flask and bioreactor. We are a dynamic and multidisciplinary group that aims to innovate, willing to collaborate with research groups around the world.

Websites

  • PUBLONS
  • Google Scholar

PeerJ Contributions

  • Edited 9

Academic Editor on

March 31, 2025
Triple negative breast cancer cells acquire lymphocyte proteins and genomic DNA during trogocytosis with T cells
Anutr Sivakoses, Haley Q. Marcarian, Anika M. Arias, Alice R. Lam, Olivia C. Ihedioha, Juan A. Santamaria-Barria, Geoffrey C. Gurtner, Alfred L. M. Bothwell
https://doi.org/10.7717/peerj.19236 PubMed 40183054
March 31, 2025
A proof-of-concept point-of-care test for the serodiagnosis of human amebic liver abscess
Rutchanee Rodpai, Penchom Janwan, Lakkhana Sadaow, Patcharaporn Boonroumkaew, Oranuch Sanpool, Tongjit Thanchomnang, Hiroshi Yamasaki, Toshihiro Mita, Pewpan M. Intapan, Wanchai Maleewong
https://doi.org/10.7717/peerj.19181 PubMed 40183058
November 29, 2024
Vascular synovial phenotype indicates poor response to JAK inhibitors in rheumatoid arthritis patients: a pilot study
Mengxia Liu, Pengcheng Liu, JianBin Li, Yiping Huang, Rui Wu
https://doi.org/10.7717/peerj.18631 PubMed 39624123
October 31, 2024
Rotating cell culture system-induced injectable self-assembled microtissues with epidermal stem cells for full-thickness skin repair
Min Zhang, Meng Huang, Xixi Dong, Yibo Wang, Luyue Zhang, Zhaoxiang Wang, Junkai Cao
https://doi.org/10.7717/peerj.18418 PubMed 39494298
October 31, 2024
Use of intravenous immunoglobulin in antiphospholipid antibody positive patients with high risk of miscarriage: a systematic review and meta-analysis
Xin Yuan, Wei Zhang, Tong Wang, Peng Jiang, Zong-kui Wang, Chang-qing Li
https://doi.org/10.7717/peerj.18419 PubMed 39494295
September 27, 2024
High microvessel and lymphatic vessel density predict poor prognosis in patients with esophageal squamous cell carcinoma
Li Wen Qi, Yu Fang Xie, Wei Nan Wang, Jia Liu, Kai Ge Yang, Kai Chen, Cheng Hua Luo, Jing Fei, Jian Ming Hu
https://doi.org/10.7717/peerj.18080 PubMed 39351370
May 23, 2024
A murine model of hypertensive heart disease in older women
Audrey Morin-Grandmont, Elisabeth Walsh-Wilkinson, Sara-Ève Thibodeau, Dominique K. Boudreau, Marie Arsenault, Yohan Bossé, Jacques Couet
https://doi.org/10.7717/peerj.17434 PubMed 38799057
May 15, 2024
Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors
Gaoxiu Qi, Xin Zhang, Xiaoying Gai, Xiong Yan
https://doi.org/10.7717/peerj.17377 PubMed 38766488
April 18, 2024
Novel monoclonal antibodies against house dust mite allergen Der p 21 and their application to analyze allergen extracts
Vytautas Rudokas, Laimis Silimavicius, Indre Kucinskaite-Kodze, Aiste Sliziene, Milda Pleckaityte, Aurelija Zvirbliene
https://doi.org/10.7717/peerj.17233 PubMed 38646484